Computer-Aided Drug Discovery Market Report 2026

The computer-aided drug discovery market size has grown rapidly in recent years. It will grow from $7.56 billion in 2025 to $8.54 billion in 2026 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increasing complexity of drug development processes, rising R&D expenditure in pharmaceuticals, expansion of computational biology capabilities, growing availability of biological data, adoption of in silico modeling techniques.

The computer-aided drug discovery market size is expected to see rapid growth in the next few years. It will grow to $13.69 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to increasing investments in ai-enabled drug discovery, rising demand for faster drug development cycles, expansion of personalized medicine research, growing integration of machine learning in pharmacology, increasing use of cloud computing for large-scale simulations. Major trends in the forecast period include increasing use of AI-driven virtual screening, rising adoption of molecular docking simulations, growing integration of genomic data in drug design, expansion of cloud-based drug discovery platforms, enhanced focus on predictive modeling accuracy.

The rising prevalence of cancer is expected to drive growth in the computer-aided drug discovery (CADD) market in the coming years. Cancer comprises a group of diseases marked by the uncontrolled growth and division of abnormal cells. The increasing incidence of cancer is influenced by factors such as lifestyle changes, urbanization, environmental pollution, tobacco and alcohol use, and varying levels of healthcare access and awareness. Computer-aided drug discovery supports the design of drugs targeting cancer cells with specific genetic mutations, enabling more personalized and effective therapies. For example, in July 2024, the Australian Institute of Health and Welfare reported approximately 165,000 new cancer cases diagnosed in 2023, with projections indicating about 204,000 annual cases by 2033, totaling an estimated 1.9 million cases between 2024 and 2033. Therefore, the rising prevalence of cancer is propelling the CADD market.

Key companies in the computer-aided drug discovery market are adopting innovative solutions, such as artificial intelligence (AI), to enhance precision, speed, and efficiency in drug discovery. AI in drug discovery uses technologies like machine learning and deep learning to accelerate identification of potential drug candidates, optimize lead compounds, and support personalized medicine development. For instance, in December 2023, Merck KGaA, a Germany-based science and technology company, launched AIDDISON™, a software-as-a-service platform integrating drug discovery and synthesis. Combining generative AI, machine learning, and computer-aided drug design, AIDDISON™ screens over 60 billion chemical targets virtually and recommends optimal synthesis routes. Trained on two decades of pharmaceutical R&D data, the platform identifies drug-like candidates with desirable properties such as non-toxicity and stability, while incorporating Merck's Synthia™ retrosynthesis API to optimize manufacturing for efficiency and sustainability, reducing both cost and time in drug development.

In October 2024, Certara Inc., a US-based provider of biosimulation software and model-informed drug-development services, acquired Chemaxon for USD 90 million. This acquisition allows Certara to integrate Chemaxon’s cheminformatics and scientific-informatics software, including tools for chemical-structure drawing, property prediction, chemical-database management, and compound registration, enhancing its drug-discovery capabilities. Chemaxon Ltd., based in Hungary, is a global provider of cheminformatics and bioinformatics software, known for widely used tools such as Marvin, JChem, and Chemicalize.

Major companies operating in the computer-aided drug discovery market are Dassault Systèmes SE, PerkinElmer Inc., Roivant Sciences Ltd., Certara Inc., Schrödinger Inc., XtalPi Inc., Dotmatics Limited, Simulations Plus Inc., ChemAxon Ltd., Exscientia Ltd., Insilico Medicine Inc., Collaborative Drug Discovery Inc., OpenEye Scientific Software Inc., Nimbus Therapeutics LLC, Atomwise Inc., GNS Healthcare Inc., BenevolentAI Limited, EpiVax Inc., Numerate Inc., Cloud Pharmaceuticals Inc., Aris Pharmaceuticals Inc., Cyclica Inc., BioSolveIT GmbH, Chemical Computing Group ULC, InSilicoTrials Technologies S.p.A.

North America was the largest region in the computer-aided drug discovery (CADD) market in 2025. The regions covered in the computer-aided drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the computer-aided drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the computer-aided drug discovery market by increasing costs of imported high-performance computing hardware, specialized processors, data storage systems, and advanced visualization equipment. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to dependence on imported computational infrastructure, while Asia-Pacific faces cost pressures on research technology procurement. These tariffs are raising infrastructure investment costs and affecting smaller research organizations. However, they are also accelerating adoption of cloud-based platforms, regional data center development, and software-centric drug discovery approaches that reduce reliance on physical hardware.

The computer-aided drug discovery market research report is one of a series of new reports that provides computer-aided drug discovery market statistics, including computer-aided drug discovery industry global market size, regional shares, competitors with a computer-aided drug discovery market share, detailed computer-aided drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the computer-aided drug discovery industry. This computer-aided drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Computer-aided drug discovery (CADD) refers to a methodology that leverages computational tools and algorithms to accelerate the identification and development of new drug candidates. It utilizes computer software and advanced technologies to design, optimize, and evaluate potential therapeutic compounds for specific biological targets.

The main approaches in computer-aided drug discovery include structure-based drug design, ligand-based drug design, and sequence-based methods. Structure-based drug design (SBDD) focuses on creating molecules guided by the three-dimensional structure of a biological target, typically a protein, obtained through techniques such as X-ray crystallography or NMR spectroscopy. These approaches are applied across therapeutic areas including oncology, neurology, cardiovascular diseases, respiratory diseases, diabetes, and more, and are utilized by end users such as pharmaceutical companies, biotechnology firms, and research laboratories.

The computer-aided drug discovery market consists of revenues earned by entities by providing molecular modeling, virtual screening, and pharmacophore modeling. The computer-aided drug discovery(CADD) market also includes sales of multi-target drug design and 3D-QSAR. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.